NGM Bio Announces $122 Million Series A Financing to Initiate a Registration Study in Primary Sclerosing Cholangitis and Fund a Phase 2 Study in Hyperemesis Gravidarum
NGM Biopharmaceuticals, Inc. The Column Group (TCG) led the round with the participation of a select group of investors Primary sclerosing cholangitis (PSC) is a...
Xapien secures $10 million in Series A funding to accelerate AI-powered transformation of the research industry
AI due diligence provider Xapien secures $10 million in Series A funding round to enhance its AI-powered due diligence platform. AI due diligence provider Xapien...
